Sah Clinical Trials
Here are the 6 most popular medical studies for sah
Behavioral
Multimedia Lifestyle Improvement for Cardiovascular Disease
This trial is testing whether a multimedia health behavior intervention can reduce cardiac risk factors in South Asians, who are a group that is especially at risk for developing these factors at younger ages and at lower body weights.
Omega-3 Fatty Acid
EPA-DHA Study for Cardiovascular Disease
The goal of the study is to test the efficacy of an EPA-enriched oil made by DuPont versus a DHA-enriched oil, a standard fish oil preparation, and olive oil placebo in a double-blind, randomized, placebo-controlled trial. This study will compare the efficacy of 1800 mg/day of EPA versus 1800 mg/day of DHA versus a fish oil product containing 1800 mg of EPA and 1200 mg of DHA/day as compared to olive oil placebo at 6 grams/day over a 6 week period in a parallel arm design study of 120 healthy adults studied in both the fasting and post-prandial state. Safety will be monitored by assessing for adverse reactions, measuring vital signs and a variety of lab tests including a complete metabolic profile and complete blood count. Efficacy will be assessed by measuring changes in fatty acid profile and or fatty acid ratios,as well as by measuring plasma lipids, lipoproteins, and markers of inflammation.
Popular filter options for sah trials
Brain Aneurysm Clinical Trials
View 12 Brain Aneurysm medical studies.
Glycocalyx for Brain Aneurysm
This study will provide novel information to the literature base for the pathophysiology of aneurysmal subarachnoid hemorrhage. The association of breakdown products in the serum of aSAH patients were reported in a very small case series of 3 patients, as mentioned above. However, while their results are intriguing and encouraging, our study will provide more definitive information about the GC in aSAH. If there is a positive correlation, the results of this study will guide future investigations into new therapies for this devastating disease such as MMP inhibition with doxycycline.
Thrombolytic Agent
Tissue Plasminogen Activator for Brain Aneurysm
The proposed study is to evaluate the acceleration the clearance of intraventricular blood (IVH) and subarachnoid hemorrhage (SAH) following ruptured intracranial aneurysms, thereby ameliorating complications, such as cerebral vasospasm, hydrocephalus and intracranial hypertension. The primary objectives are: Estimate the rate and variance of hematoma clearance following aneurysmal SAH, thereby facilitating sample size determination for a subsequent larger study; Assess the feasibility of a randomized controlled trial of intraventricular tissue plasminogen activator (TPA) among patients with SAH (enrollment rate, ability to blind investigators, protocol compliance); Confirm the safety of intraventricular TPA.
View More Sah Trials
See another 14 medical studies focused on sah.
Frequently Asked Questions
Introduction to sah
What are the top hospitals conducting sah research?
When it comes to the cutting-edge research and clinical trials in Subarachnoid Hemorrhage (SAH), several top hospitals are leading the way. Foothills Medical Center, located in Calgary, has emerged as a prominent player with two active SAH trials and a total of two completed studies since their first recorded trial back in 2009. Moving southward to Columbus, Ohio, we find The Ohio State University Wexner Medical Center making valuable contributions with one ongoing SAH trial and an additional two completed trials dating back to 2016.
Further west, Stanford University situated in Palo Alto continues to push the boundaries of medical innovation by currently conducting one active SAH trial while having accomplished another study previously. Interestingly enough, both institutions have made significant strides recently as they each recorded their very first SAH trial only this year (2021).
In Aurora at the University of Colorado Anschutz Medical Campus, researchers are similarly exploring new frontiers with one ongoing SAH trial alongside a single previously conducted study - both initiated this year. Meanwhile, Our Lady of the Lake Regional Medical Center in Baton Rouge also joins this group as they actively participate in one clinical trial for SAH while having successfully completed another investigation.
These healthcare facilities serve patients not only within their local communities but also attract individuals seeking advanced medical care from across the nation. Together these institutions illustrate that progress is being made through dedicated efforts and groundbreaking research towards understanding and treating Subarachnoid Hemorrhage events—bringing hope to patients affected by this condition worldwide.
Which are the best cities for sah clinical trials?
In the realm of SAH (subarachnoid hemorrhage) clinical trials, several cities have emerged as hotspots for research and innovation. Nashville, Tennessee leads the pack with 4 ongoing trials investigating treatments like N-acetylcysteine and acetaminophen. Baltimore, Maryland follows closely behind with 3 active studies focused on interventions such as Neuromuscular Electrical Stimulation (NMES), Integrated AUD Treatment, and Docosahexaenoic Acid. Additionally, San Antonio, Texas; Durham, North carolina; and Boston Massachusetts each contribute to advancing SAH care through their respective active trials exploring a range of potential treatments. These cities serve as hubs of medical progress in the field of subarachnoid hemorrhage clinical research.
Which are the top treatments for sah being explored in clinical trials?
Clinical trials exploring treatments for subarachnoid hemorrhage (SAH) have highlighted some promising options. The CerebroFlo™ EVD Catheter, introduced in 2021, is currently being tested in one active SAH trial and has shown potential as a therapeutic approach. Another innovative treatment is auricular vagus nerve stimulation, which also made its debut in 2021 and is under investigation in one ongoing SAH trial. Furthermore, the regional anesthetic SPG block-bilateral technique, listed since 2020, offers another avenue of exploration with its involvement in one active SAH trial. These cutting-edge treatments hold promise for improving outcomes for patients affected by this condition.
What are the most recent clinical trials for sah?
Exciting developments are occurring in the field of subarachnoid hemorrhage (SAH) with recent clinical trials offering potential advancements in treatment. One such trial involves the use of deferoxamine, a medication being investigated in Phase 2 studies for SAH patients. Another study explores the continuous administration of antibiotics until an external ventricular drain is removed, aiming to improve outcomes after SAH. Additionally, Phase 1 trials have examined regional anesthetic SPG block-bilateral and deferiprone pills as potential interventions for SAH. Although these trials are still ongoing or at early stages, they represent significant steps towards enhancing patient care and management following SAH events.
What sah clinical trials were recently completed?
In recent years, several clinical trials focusing on subarachnoid hemorrhage (SAH) have come to fruition, bringing new insights and advancements in the field. Notably, a trial sponsored by the University of Wisconsin, Madison investigated the potential of Acetazolamide and concluded in July 2019. Similarly, Idorsia Pharmaceuticals Ltd. conducted a trial testing Clazosentan with SAH patients, completing their study in December 2018. These completed trials contribute valuable data to inform future approaches for SAH treatment and underline ongoing efforts to improve outcomes for individuals affected by this condition.